<code id='6C0AC2581C'></code><style id='6C0AC2581C'></style>
    • <acronym id='6C0AC2581C'></acronym>
      <center id='6C0AC2581C'><center id='6C0AC2581C'><tfoot id='6C0AC2581C'></tfoot></center><abbr id='6C0AC2581C'><dir id='6C0AC2581C'><tfoot id='6C0AC2581C'></tfoot><noframes id='6C0AC2581C'>

    • <optgroup id='6C0AC2581C'><strike id='6C0AC2581C'><sup id='6C0AC2581C'></sup></strike><code id='6C0AC2581C'></code></optgroup>
        1. <b id='6C0AC2581C'><label id='6C0AC2581C'><select id='6C0AC2581C'><dt id='6C0AC2581C'><span id='6C0AC2581C'></span></dt></select></label></b><u id='6C0AC2581C'></u>
          <i id='6C0AC2581C'><strike id='6C0AC2581C'><tt id='6C0AC2581C'><pre id='6C0AC2581C'></pre></tt></strike></i>

          
          WSS
          translucent 3D DNA helix with blue and purple background
          Adobe

          Verve Therapeutics said Monday that it had received clearance from the Food and Drug Administration to conduct a clinical trial in the U.S. of its experimental, gene-editing treatment for a common form of heart disease.

          The FDA’s action removes a clinical hold on Verve’s CRISPR-based therapy, called VERVE-101, that was placed on it last November. Verve now intends to recruit participants from U.S. sites into a Phase 1 study that’s been underway since last year in New Zealand and the United Kingdom.

          advertisement

          “We’re thrilled to get this clearance for VERVE-101,” said Verve CEO Sek Kathiresan. “Our study is called HEART-1 and our plan now is to activate U.S. sites.”

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          knowledge